|Bid||4.0400 x 1200|
|Ask||4.0500 x 1000|
|Day's Range||4.0300 - 4.2300|
|52 Week Range||3.9500 - 36.1050|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.75|
Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) * Agenus Inc (NASDAQ: AGEN) * Akouos Inc (NASDAQ: AKUS) * BioLife Solutions Inc (NASDAQ: BLFS) * Checkpoint Therapeutics Inc (NASDAQ: CKPT) * ESSA Pharma Inc (NASDAQ: EPIX) * Fortress Biotech (NASDAQ: FBIO) * Harmony Biosciences Holdings Inc (NASDAQ: HRMY) * Inspire Medical Systems Inc (NYSE: INSP) * Kintara Therapeutics Inc (NASDAQ: KTRA) * Kura Oncology Inc (NASDAQ: KURA) * Protagonist Therapeutics Inc (NASDAQ: PTGX) * RedHill Biopharma Ltd (NASDAQ: RDHL) * Silk Road Medical Inc (NASDAQ: SILK) * Shockwave Medical Inc (NASDAQ: SWAV) * Trillium Therapeutics Inc (NASDAQ: TRIL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC)(reacted to results for the half-year) * Burning Rock Biotech Ltd (NASDAQ: BNR) * Evofem Biosciences Inc (NASDAQ: EVFM) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Pandion Therapeutics Inc (NASDAQ: PAND) * Satsuma Pharmaceuticals Inc (NASDAQ: STSA) (reacted to a negative late-stage clinical readout for investigational migraine drug)Stocks In Focus Roche Presents Positive Long-Term Data For Multiple Sclerosis Drug Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS meeting new data that showed Ocrevus is a highly effective treatment option for people with relapsing-remitting multiple sclerosis who experienced a suboptimal response to their prior disease modifying therapy.Further subgroup analysis from the two-year, open-label Phase 3b CASTING study also demonstrated that patients benefit across a wide range of disease related and demographic subgroups regardless of prior treatment background, Roche said.Galapagos Reports Positive Midstage Results For Autoimmune Disease Drug GALAPAGOS NV/S ADR (NASDAQ: GLPG) announced positive topline results for the NOVESA Phase 2a clinical trial with investigational ziritaxestat in patients with diffuse cutaneous systemic sclerosis, or dcSSc."Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo," Galapagos said.The Phase 2a proof-of-concept trial evaluated the efficacy, safety and tolerability of ziritaxestat in 33 patients with dcSSc, a severe autoimmune disease, for which there is no approved drug.In premarket trading, Galapagos shares were rising 8.9% to $136.99. See also: The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations Lyra's LYR-210 Found Effective In Chronic Rhinosinusitis Lyra Therapeutics Inc (NASDAQ: LYRA) presented at the 66th Annual Meeting of the American Rhinologic Society data showing that its LYR-210 demonstrated a significant reduction of sinonasal type 2 inflammation in surgically naive patients with chronic rhinosinusitis.Intersect ENT Announces Agreement With Walgreens For Distributing Sinus Implant Intersect ENT Inc (NASDAQ: XENT) said it has signed a pharmacy services agreement with Walgreens Boots Alliance Inc's (NASDAQ: WBA) AllianceRx Walgreens Prime for national specialty pharmacy distribution of the its Sinuva Sinus Implant."The agreement will facilitate broader physician and patient access to Sinuva by using the expertise and established specialty pharmacy infrastructure of AllianceRx Walgreens Prime to dispense SINUVA through either a patient's medical or pharmacy insurance benefit," Intersect ENT said.Sol Gel Says FDA Accepts Regulatory Filing For Skin Inflammation Drug Sol Gel Technologies Ltd (NASDAQ: SLGL), a clinical-stage dermatology company, said its NDA for Epsolay, an investigational proprietary topical cream for the treatment of inflammatory lesions of rosacea containing 5% encapsulated benzoyl peroxide, has been accepted for filing by the FDA.The PDUFA date has been set for April 26, 2021.The stock was trading 5.14% higher to $7.98 premarket Friday. On The Radar Clinical Readouts Atara Biotherapeutics Inc (NASDAQ: ATRA) is scheduled to present at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS meeting with new 12-month data from all four cohorts in the Phase 1a study of ATA188 for the treatment of progressive forms of multiple sclerosisRelated Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates See more from Benzinga * Gilead Analysts Trim Expectations After 'Very Unexpected' Adverse FDA Ruling * The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In .5B Deal, 2 IPOs * The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Satsuma Pharmaceuticals (NASDAQ: STSA) are plunging today, down 74.8% as of 11:17 a.m. EDT, after the company announced that investigational drug STS101 failed to meet the primary endpoints in a phase 3 study in treating migraine. Neither the 3.9 mg nor the 5.2 mg dose of the nasal powder achieved statistically significant improvement in the key symptoms of migraine at two hours after administration. Satsuma CEO John Kollins said that the company was "surprised and disappointed" by these results.